The United Kingdom and the United States have finalized a major commercial pact that will maintain no tariffs on UK pharmaceutical shipments being sold in the American market.
Key Provisions of the Pact
In exchange for the tariff guarantee, the UK has pledged to increase spending on drugs through the public health system. This pledge guarantees that duties on these crucial goods will be held at nothing for a period of 36 months.
This agreement is in response to recent statements to significantly raise import taxes on patented pharmaceutical imports, with increases discussed as high as 100%.
"This deal between the United Kingdom strengthens the global environment for cutting-edge drugs and brings much-needed fairness to transatlantic pharmaceutical trade," a release said.
Trade Impact
Drugs constitute one of the Britain's largest exports to the America, which is clearly the primary market for large companies like GSK and AstraZeneca.
Export figures indicate that in the 12 months prior to September, the UK sold medicines valued at £11.1bn to the US. This amount made up nearly one-fifth of all goods exports in that span.
"This deal secures employment, increases capital expenditure and sets the stage for the UK to establish itself as a international leader for medical research," a minister commented.
Specific UK Commitments
The deal entails several key pledges from the UK:
- Price Threshold Increase: The UK will raise the price threshold at which it judges new treatments to be unaffordable by twenty-five percent.
- Increased NHS Spending: There is a goal to increase overall public funding on treatments from 0.3% of Gross Domestic Product to 0.6% over the following ten-year period.
- Rebate Cap: The percentage drug companies must pay back to the NHS to stay within budget will be capped at 15%. Last year, refunds exceeded 20%.
Recent Tensions
The deal follows a long-running tension between the drug companies and the British authorities over drug pricing and regulatory access.
These tensions were heightened by claims that US customers were paying significantly more for the equivalent treatments than people in the UK and Europe.
Recently, several significant manufacturing plans in the UK have been halted or cancelled, while multi-billion-dollar funding commitments have been announced toward US facilities.
A senior figure acknowledged that the NHS needed to increase expenditure on drugs, noting that its budget allocation on drugs had decreased as a percentage of its overall budget over the previous ten-year period.
